Grace Net Income From Continuing Ops from 2010 to 2024

GRCE Stock   3.44  0.16  4.88%   
Grace Therapeutics,'s Net Loss is increasing over the years with very volatile fluctuation. Net Loss is expected to dwindle to about -13.5 M. During the period from 2010 to 2024 Grace Therapeutics, Net Loss annual values regression line had coefficient of variation of (35.94) and r-squared of  0.0005. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-12.9 M
Current Value
-13.5 M
Quarterly Volatility
7.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Grace Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Grace Therapeutics,'s main balance sheet or income statement drivers, such as Net Interest Income of 956.5 K, Interest Income of 956.5 K or Interest Expense of 0.0, as well as many indicators such as . Grace financial statements analysis is a perfect complement when working with Grace Therapeutics, Valuation or Volatility modules.
  
Check out the analysis of Grace Therapeutics, Correlation against competitors.
For information on how to trade Grace Stock refer to our How to Trade Grace Stock guide.

Latest Grace Therapeutics,'s Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Grace Therapeutics, over the last few years. It is Grace Therapeutics,'s Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Grace Therapeutics,'s overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Very volatile
   Net Income From Continuing Ops   
       Timeline  

Grace Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(19,670,310)
Coefficient Of Variation(35.94)
Mean Deviation3,045,771
Median(19,678,000)
Standard Deviation7,069,093
Sample Variance50T
Range32.6M
R-Value0.02
Mean Square Error53.8T
R-Squared0.0005
Significance0.94
Slope35,384
Total Sum of Squares699.6T

Grace Net Income From Continuing Ops History

2024-13.5 M
2023-12.9 M
2022-42.4 M
2021-9.8 M

About Grace Therapeutics, Financial Statements

Grace Therapeutics, stakeholders use historical fundamental indicators, such as Grace Therapeutics,'s Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Grace Therapeutics, investors may analyze each financial statement separately, they are all interrelated. For example, changes in Grace Therapeutics,'s assets and liabilities are reflected in the revenues and expenses on Grace Therapeutics,'s income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Grace Therapeutics,. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-12.9 M-13.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Grace Therapeutics, is a strong investment it is important to analyze Grace Therapeutics,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Grace Therapeutics,'s future performance. For an informed investment choice regarding Grace Stock, refer to the following important reports:
Check out the analysis of Grace Therapeutics, Correlation against competitors.
For information on how to trade Grace Stock refer to our How to Trade Grace Stock guide.
You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Grace Therapeutics,. If investors know Grace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Grace Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Grace Therapeutics, is measured differently than its book value, which is the value of Grace that is recorded on the company's balance sheet. Investors also form their own opinion of Grace Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Grace Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Grace Therapeutics,'s market value can be influenced by many factors that don't directly affect Grace Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Grace Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Grace Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Grace Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.